If the label smears or appears misaligned ... Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo Nordisk is the ...

In a 72-week study, 37% of participants receiving Wegovy saw improvement in liver fibrosis, compared to 22.5% in the placebo group. Novo Nordisk said it plans to seek an expanded Wegovy label in 2025.

like Wegovy, are approved for weight loss in patients with an obese body mass index or who are overweight and have a weight-related health condition like high blood pressure. Still, plenty are ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy. NFL News: ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide ...